J Cardiol. 2026 Jul 30:S0914-5087(26)00156-5. doi: 10.1016/j.jjcc.2026.07.017. Online ahead of print.
ABSTRACT
Aim The dilated phase of hypertrophic cardiomyopathy (D-HCM) is associated with poor clinical outcomes. Cardiac resynchronization therapy (CRT) is an established treatment for heart failure; however, its efficacy in D-HCM, particularly in Japanese patients, remains unclear. This study aimed to evaluate clinical status after CRT in patients with D-HCM. METHODS AND RESULTS: We retrospectively identified patients with D-HCM who received CRT and were followed at Kochi Medical School Hospital between October 2004 and December 2021. Among 325 patients with HCM, 35 (10.8%) progressed to D-HCM during follow-up, and nine of these patients (25.7%) underwent CRT. Median age at CRT implantation was 64 years. At baseline, five patients (56%) were in New York Heart Association (NYHA) class II and four (44%) in class III. After CRT, eight of nine patients showed improvement or remained in NYHA class II. No statistically significant changes were observed in B-type natriuretic peptide levels or left ventricular ejection fraction after CRT. The median time to first unplanned cardiovascular hospitalization after CRT was approximately one year. CONCLUSION: In this Japanese regional D-HCM cohort, symptomatic improvement or stabilization was observed after CRT, although the findings should be interpreted cautiously because of limited sample size and concomitant medication management.
PMID:42532261 | DOI:10.1016/j.jjcc.2026.07.017